Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) FCF Margin (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed FCF Margin for 14 consecutive years, with 24.12% as the latest value for Q4 2025.

  • Quarterly FCF Margin rose 625.0% to 24.12% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1.11% through Dec 2025, down 144.0% year-over-year, with the annual reading at 3.26% for FY2025, 63.0% down from the prior year.
  • FCF Margin for Q4 2025 was 24.12% at Aytu Biopharma, up from 4.45% in the prior quarter.
  • The five-year high for FCF Margin was 30.47% in Q2 2023, with the low at 38.15% in Q4 2021.
  • Average FCF Margin over 5 years is 5.97%, with a median of 7.65% recorded in 2024.
  • The sharpest move saw FCF Margin plummeted -5454bps in 2022, then surged 5624bps in 2023.
  • Over 5 years, FCF Margin stood at 38.15% in 2021, then soared by 76bps to 9.33% in 2022, then skyrocketed by 92bps to 0.72% in 2023, then skyrocketed by 2582bps to 17.87% in 2024, then surged by 35bps to 24.12% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 24.12%, 4.45%, and 18.41% for Q4 2025, Q3 2025, and Q2 2025 respectively.